Edition:
United Kingdom

Medigene AG (MDG1k.DE)

MDG1k.DE on Xetra

12.78EUR
12:57pm GMT
Change (% chg)

€-0.48 (-3.62%)
Prev Close
€13.26
Open
€13.33
Day's High
€13.40
Day's Low
€12.60
Volume
340,793
Avg. Vol
299,585
52-wk High
€15.24
52-wk Low
€8.53

Chart for

About

Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modi... (more)

Overall

Beta: 1.27
Market Cap(Mil.): €287.57
Shares Outstanding(Mil.): 22.30
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Medigene, RXi To Collaborate On Therapeutic T Cells

* MEDIGENE COLLABORATES WITH RXI PHARMACEUTICALS TO FURTHER SHARPEN ITS THERAPEUTIC T CELLS

11 Dec 2017

BRIEF-Medigene Sells US-Rights For Veregen, Raises 2017 Guidance

* PTA-ADHOC: MEDIGENE AG: MEDIGENE SELLS US-RIGHTS FOR VEREGEN® AND RAISES FINANCIAL GUIDANCE 2017

05 Dec 2017

BRIEF-Medigene to issue new shares to settle Trianta milestone payment

* Announces issuance and number of new shares to settle last Trianta milestone payment

07 Sep 2017

BRIEF-Medigene H1 total revenue at EUR 4.9 mln​

* H1 ‍REVENUE FROM CORE BUSINESS IMMUNOTHERAPIES (BLUEBIRD BIO PARTNERSHIP) AMOUNTS TO EUR2,252 K (6M 2016: EUR0 K)​

03 Aug 2017

BRIEF-Medigene submits CTA for its first TCR clinical trial

* PTA-ADHOC: MEDIGENE AG: MEDIGENE SUBMITS CTA FOR ITS FIRST TCR CLINICAL TRIAL AND ANNOUNCES MILESTONE PAYMENT

10 Jul 2017

Earnings vs. Estimates